Fortis Healthcare Limited

Employee Stock Option Schemes (ESOSs)

Disclosure Pursuant to Regulation 14 of Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021

1. GENERAL DISCLOSURES

- a. Relevant disclosures in terms of the accounting standards prescribed by the Central Government in terms of section 133 of the Companies Act, 2013 (18 of 2013) including the 'Guidance note on accounting for employee share-based payments' issued in that regard from time to time
- b. Diluted Earnings Per Share in accordance with "Ind AS-33-Earning Per Share" for the year ended March 31, 2024 stood at Rs. 7.93 (as per Consolidated Financials Statement)

2. SCHEME SPECIFIC DISCLOSURES

i. General Disclosures

S. No.	Particulars	Disclosures (ESOP 2007)	Disclosures (ESOP 2011)
1	Date of Shareholder's Approval	September 27, 2007	September 19, 2011 modified w.e.f. September 29, 2012
2	Total Number of options approved under ESOP Scheme 2008	22,66,665	12,154,825
3	Vesting requirements	A five year vesting schedule would apply on all the options granted as given below: • 20% options shall vest on the completion of 12 months from grant date • 20% options shall vest on the completion of 24 months from grant date • 20% options shall vest on the completion of 36 months from grant date • 20% options shall vest on the completion of 48 months from grant date • 20% options shall vest on the completion of 48 months from grant date • 20% options shall vest on the completion of 60 months from the grant date	100 % after lock in of three years from the grant date
4	Exercise Price or Pricing Formula	of the Company on the stock	The Exercise Price can be higher but shall not be less than the closing market price of the Company's Shares on the Stock

S. No.	Particulars	Disclosures (ESOP 2007)	Disclosures (ESOP 2011)
		the date of meeting of the Remuneration Committee in which stock options are granted. If the shares are listed on more than one stock exchange, then the stock exchange where there is highest trading volumes on the	Exchange showing highest volume of trading, on the day prior to the date of grant, as determined by the Committee. In case where there is no trading on any recognized stock exchange, the exercise price will be (a) the closing price of the shares on any recognized stock exchange on a date closest to the date of grant of the options and immediately preceding such date; or the closing price of the share on a recognized stock exchange, which records the highest volume in such share, if the closing price, as on the date closest to the date of grant of option and immediately preceding such date, is recorded on more than one recognized stock exchange
5	Maximum term of Options Granted	10 years from the date of grant of the Options	4 years from the date of Vesting
6	Sources of Share (Primary, Secondary or Combination)	Primary	Primary
7	Variation in terms of Options	No	The Employee Stock Option Plan, 2011 (ESOP Scheme) was modified to provide for facilitating the offer, issuance and allotment, in tranche(s), such number of Stock Options / Equity Shares through the 'Fortis Healthcare Limited Employees Welfare Trust' to the eligible employees and Directors, upon the instructions of the Board of Directors or HR & Remuneration Committee thereof.
8	Method used for Accounting of ESOS (Intrinsic or Fair Value)	Fair Value	Fair Value
9 (a)	Difference, if any, between employee compensation cost calculated using the intrinsic value of stock options and employee compensation cost calculated on the basis of fair value of stock options	N/A	N/A
9(b)	Impact on the profits of the Company and on the	N/A, Impact on EPS:- (0.00)	N/A, Impact on EPS:- (0.00)

S. No.	Particulars	Disclosures (ESOP 2007)	Disclosures (ESOP 2011)
	earnings per share ("EPS") arising due to difference in the accounting treatment and for calculation of the employee compensation cost (i.e. difference of the fair value of stock options over the intrinsic value of the stock options)		
10	 a) Weighted average exercise price, b) weighted average fair value of options whose exercise price either equals or exceeds or is less than market price of the stock 		

ii. Options Movement during the FY 2022–23

S.No.	Particulars	Disclosures (ESOP	Disclosures (ESOP
		2007)	2011)
1	Number of options outstanding at the	-	-
	beginning of the period		
2	Number of options granted during the year	-	-
3	Number of options forfeited / lapsed during the	-	-
	year		
4	Number of options vested during the year	-	-
5	Number of options exercised during the year	-	-
6	Number of shares arising as a result of exercise	-	-
	of options		
7	Money realized by exercise of options (INR), if	-	-
	scheme is implemented directly by the		
	company		
8	Loan repaid by the Trust during the year from	-	-
	exercise price received		
9	Number of options outstanding at the end of	-	-
	the year		
10	Number of options exercisable at the end of the	-	-
	year		

iii. Employees Details who were granted options during the year

S. No.	Particulars	Name of Employee	Designation	Number of options granted during the	Exercise Price
				year	

Key Managerial Personnel and Senior Managerial Personnel	NIL
Employee who received grant in any one year equal to or more than 5% of Options granted during the Year	
Identified Employees who were granted option, during any one year, equal to or exceeding 1% of the issued capital (excluding outstanding warrants and conversions) of the company at the time of grant	

iv. Accounting Method and Assumptions

Method used for ESOPs	Disclosures (ESOP 2007)	Disclosures (ESOP 2011)
Risk free interest rate	7.65% - 8.70%	7.37%-8.24%
Expected Life	10 Years	5 Years - 7 Years
Expected Volatility	6.42% - 66.24%	22.91% - 31.93%
Expected Dividends	0%	0%
Price of underlying shares in market at the time of Option grant	49.05 – 158	90.35 – 194.55

the method used and the assumptions made to incorporate the effects of expected early exercise;

how expected volatility was determined, including an explanation of the extent to which expected volatility was based on historical volatility; and

whether and how any other features of the options granted were incorporated into the measurement of fair value, such as a market condition.

For & on behalf of Board of Directors of Fortis Healthcare Limited

Sd/-Ashutosh Raghuvanshi MD&CEO

Date: May 23, 2024 Place: Gurgaon